Node-RADS for preoperative locoregional nodal staging of endometrial cancer: reproducibility and accuracy assessment using CT and MRI - Takeaways - MDSpire

Node-RADS for preoperative locoregional nodal staging of endometrial cancer: reproducibility and accuracy assessment using CT and MRI

  • By

  • Matteo Bonatti

  • Riccardo Valletta

  • Valentina Corato

  • Bernardo Proner

  • Laurjan Hoxha

  • Luca Odoferdi

  • Martin Steinkasserer

  • Roberta Valerieva Ninkova

  • Giacomo Avesani

  • Vincenzo Vingiani

  • Lucia Manganaro

  • August 20, 2025

  • 0 min

Share

  • 1

    Endometrial cancer is the most common gynecological malignancy in Europe, with rising prevalence linked to aging and obesity.

  • 2

    Node-RADS was introduced to improve the accuracy and reproducibility of lymph node evaluation in preoperative staging of endometrial cancer.

  • 3

    The study assessed the diagnostic accuracy of Node-RADS among readers with varying expertise using CT and MRI images.

  • 4

    Inter-reader reproducibility of Node-RADS requires further investigation, as diagnostic accuracy remains unsatisfactory in preoperative nodal staging.

  • 5

    The study included 165 patients with histologically proven endometrial cancer who underwent preoperative pelvic MRI staging.

Original Source(s)

Node-RADS for preoperative locoregional nodal staging of endometrial cancer: reproducibility and accuracy assessment using CT and MRI

  • by Matteo Bonatti, Riccardo Valletta, Valentina Corato, Bernardo Proner, Laurjan Hoxha, Luca Odoferdi, Martin Steinkasserer, Roberta Valerieva Ninkova, Giacomo Avesani, Vincenzo Vingiani, Lucia Manganaro

  • August 20, 2025

Related Content

Lactate–Albumin Ratio Tied to TBI Mortality

Admission biomarker showed prognostic value alongside clinical scoring systems in pediatric intensive care

AI Falls Short on Differential Dx

New PrIME-LLM benchmark shows strong diagnostic accuracy but persistent gaps in clinical reasoning across 21 large language models

FDA Grants Accelerated Approval for OTOF Gene Therapy

A one-time intracochlear gene therapy improved hearing outcomes in patients with OTOF-related sensorineural hearing loss in the phase 1/2 CHORD trial.